Search
Tivozanib
go.drugbank.com/drugs/DB11800ApprovedInvestigationalRenal cell carcinoma (RCC) is responsible for 3% of cancer cases and is one of the 10 most common cancers in adults. The average age of diagnosis is between age 65 to 74. Tivozanib, also known as FOTIVDA, is a kinase inhibitor developed ...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesNeratinib
go.drugbank.com/drugs/DB11828ApprovedInvestigationalNeratinib was approved in July 2017 for use as an extended adjuvant therapy in Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer. Approval was granted to Puma Biotechnology Inc. for the tradename Nerlynx. Neratinib i...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesDeflazacort
go.drugbank.com/drugs/DB11921ApprovedDeflazacort, also known as Emflaza, is a corticosteroid prodrug used as an agent to manage Duchenne Muscular Dystrophy (DMD). It is marketed by Marathon Pharmaceuticals and was approved in February 2017 by the FDA. Duchenne Muscular Dyst...
Categories: Cytochrome P-450 CYP3A Inducers, Cytochrome P-450 SubstratesDelafloxacin
go.drugbank.com/drugs/DB11943ApprovedInvestigationalDelafloxacin is a fluoroquinolone antibiotic which has been used in trials studying the treatment and basic science of Gonorrhea, Hepatic Impairment, Bacterial Skin Diseases, Skin Structure Infections, and Community Acquired Pneumonia, a...
Categories: Cytochrome P-450 CYP2C9 Inducers, Cytochrome P-450 CYP2E1 InducersLemborexant
go.drugbank.com/drugs/DB11951ApprovedInvestigational[L10863] Recent research in the field of sleep disorders has revealed that insomnia is likely driven not by the inability of the brain to "switch on" sleep-related circuits, but rather an inability to
Categories: Cytochrome P-450 CYP2B6 Inducers, Cytochrome P-450 CYP3A InducersDuvelisib
go.drugbank.com/drugs/DB11952ApprovedInvestigationalDuvelisib, also known as IPI-145 and INK-1197, is a small-molecule inhibitor of phosphoinositide-3 kinases that was designed initially to prove that simultaneous inhibition of the isoforms delta and gamma can produce a broad adaptative a...
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesAvatrombopag
go.drugbank.com/drugs/DB11995ApprovedInvestigational[A33095] Thrombocytopenia is a common complication in patients suffering from chronic liver disease, occurring as a result of liver disease or a consequence of interferon-based antiviral therapy.
Categories: Cytochrome P-450 CYP2C8 Inducers, P-glycoprotein substratesFostamatinib
go.drugbank.com/drugs/DB12010ApprovedInvestigationalFostamatinib has been investigated for the treatment and basic science of Rheumatoid Arthritis and Immune Thrombocytopenic Purpura (ITP). It was approved on April 17, 2018, under the trade name Tavalisse for use in ITP . Fostamatinib has...
Categories: Cytochrome P-450 CYP3A Inhibitors, Cytochrome P-450 SubstratesAlpelisib
go.drugbank.com/drugs/DB12015ApprovedInvestigationalAlpelisib is a phosphatidylinositol 3-kinase (PI3K) inhibitor with potent antitumor activity. It works by selectively inhibiting class I PI3K p110α , which is the catalytic subunit of PI3K, a lipid kinase that plays a role in various bio...
Categories: Cytochrome P-450 CYP2B6 Inducers, P-glycoprotein inhibitorsLandiolol
go.drugbank.com/drugs/DB12212ApprovedInvestigationalLandiolol is a rapid-acting beta (β)-1 adrenergic receptor blocker that blocks the positive chronotropic effect of the beta-1 selective agonist norepinephrine. It works to reduce the heart rate, myocardial contractility, and conduction v...
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2D6 Inhibitors